Enterococci are part of the normal human flora. Enterococcus faecalis und Enterococcus faecium are the most common species isolated from human infections. Vancomycinresistant enterococci (VRE) have emerged as a major cause of nosocomial infection as early as 1986 [1] . 10 years later, >15% of nosocomial enterococcal infections in United States hospitals were due to VRE, and even higher in intensive care units. E. faecium is the most commonly identified species identified. Enterococci are inherently resistant to many antibiotics, in particular to all cephalosporins. Today, >80% of all strains of E. faecium are ampicillinresistant in Switzerland (www.anresis.ch), and approximately 5% are VRE. In contrast, E. faecalis remains susceptible to ampicillin in 97%, and detection of VRE among E. faecalis is rare. VRE belong to the multiresistant pathogens that rapidly spread and are difficult to treat [1, 2] Inducible vancomycin resistance in enterococci is due to a sophisticated mechanism that combines synthesis of cell wall peptidoglycan precursors with low affinity for glycopeptides and elimination of the normal target precursors. Similar to other multiresistant pathogens, VRE was observed in Europe, and in 1994, VRE were first isolated in Switzerland [3, 4] . Vancomycin resistance is seen in addition to E. faecium and E. faecalis, but also has been recognised in E. raffinosus, E. avium, E. durans, and several other enterococcal species. Several genes, including vanA, vanB, vanC, vanD, and vanE, contribute to resistance to vancomycin in enterococci. Multiple epidemics have been described with VRE, predominantly with genotype vanA. Phenotype VanA and VanB are common in the USA, but phenotype Van C appears to be more prevalent in Europe (table) [5, 6] . The emergence and spread of VRE VanC in Europe is related to the use of the growth promoter avoparcin in animal husbandry. Avoparcin is a glycopeptide produced by Streptomyces candidus, closely related to vancomycin. It was banned in 1997, and subsequently, VRE VanC decreased in European hospitals. Knowledge of the type of resistance is critical for infection control purposes: vanA or vanB genes are transferable and can spread from organism to organism.
New screening plates such as chromID™ VRE detect VanA and Vanc B enterococci, but inhibit growth of VanC enterococci. Enterococci of vanC phenotype are not transferable, have been associated less commonly with serious infections, and have rarely caused outbreaks. In fact, our own data clearly indicate that the low risk for transmission of VRE of phenotype VanC does not justify contact isolation [7] . Many hemato-oncology patients are only colonised with VRE, that precede bloodstream infections [8] . VRE is As a rule of thumb, VRE strains isolated from a clinical sample in the routine microbiology laboratory usually indicates that 10 other patients on that ward are colonized if they would be screened. Therefore, one clinical isolation of VRE should always prompt a large epidemiological workup that includes an epidemiologic curve, screening of patients in contact with the index case, and molecular typing of these strains. Our own data (unpublished) show that it takes less than a couple hours for recontamination with enterococci even after a thorough disinfection of a ward. Patients may remain colonised for months and even years. Therefore, as the example of the outbreaks in Lausanne showed in 2011, a long-term intervention is necessary to stop such outbreaks. At the University Hospital of Basel, such a large-scale intervention in 1999 stopped a cluster, and nosocomial VRE were no longer detected >10 years despite active screening with enrichment cultures. VRE control is feasible, but takes a lot of effort, stamina, and restriction of vancomycin use, strict contact isolation of colonised patients, environmental control and sometimes even closure of a ward. Only large-scale interventions are successful, limited targeted activities are futile and not costeffective in the long-term. The examples from Zurich and more recently from Lausanne support this statement.
Funding / potential competing interests: No financial support and no other potential conflict of interest relevant to this article was reported.
